minretumomab
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 1996 (NCT00002734)
Timeline
1990s
- Jan 1, 1996
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor-associated antigen 72BINDING AGENT
Tumor-associated antigen 72 binding agent
- TAG72Immunity, passive
TAG72 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109580 ↗
- ChEMBLCHEMBL2108796 ↗
Also known as
- cc49-deltach2
- lu177 monoclonal antibody cc49
- mab-cc49
- minretumomab
- y90 monoclonal antibody cc49
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00023933 | Phase 1 | Oct 1, 2001 | National Cancer Institute (NCI), University of Alabama, Birmingham |
| NCT00002734 | Phase 1 | Mar 1, 1996 | National Cancer Institute (NCI), University of Alabama, Birmingham |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 1996 |
| University of Alabama, Birmingham | Academic/Hospital | 2 | 0 | 1 | 1996 |
2 organizations
Page 1 / 1